Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jan;61(1):147–150. doi: 10.1038/bjc.1990.30

The response of cerebral metastases in small cell lung cancer to systemic chemotherapy.

C J Twelves 1, R L Souhami 1, P G Harper 1, C M Ash 1, S G Spiro 1, H M Earl 1, J S Tobias 1, H Quinn 1, D M Geddes 1
PMCID: PMC1971312  PMID: 2153393

Abstract

Although small cell lung cancer (SCLC) is very chemosensitive, cerebral metastases are treated with radiotherapy in the belief that they are protected from chemotherapy by the blood-brain barrier (BBB). The validity of this assumption has not been tested in clinical practice. In a randomised trial of treatment in 610 patients with SCLC, 19 patients who had symptomatic cerebral metastases at presentation were treated initially with chemotherapy, and cranial irradiation withheld. Chemotherapy was cyclophosphamide 1 g m-2 i.v. day 1, vincristine 2 mg i.v. day 1 and etoposide 100 mg tds p.o. days 1-3, repeated every 21 days, with response assessed objectively by computerised tomography (CT) or radionuclide brain scan, and by clinical examination. A post-chemotherapy scan was obtained in 14 patients, eight of whom achieved a partial remission and one a complete remission of the cerebral metastases. The radiologically proven responses were sustained and accompanied by rapid neurological improvement. Of the remaining five patients who were assessed by clinical examination alone, one had improved neurological function after chemotherapy. The response rate for SCLC cerebral metastases treated with chemotherapy was therefore 10/19 (53%). Chemotherapy has the advantage over cranial irradiation of simultaneously treating both cerebral metastases and extracranial disease. The place of chemotherapy in the management of cerebral metastases in this and other chemosensitive tumours should be reconsidered since these findings indicate that the BBB does not prevent response to chemotherapy.

Full text

PDF
147

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cairncross J. G., Kim J. H., Posner J. B. Radiation therapy for brain metastases. Ann Neurol. 1980 Jun;7(6):529–541. doi: 10.1002/ana.410070606. [DOI] [PubMed] [Google Scholar]
  2. Cox J. D., Komaki R., Byhardt R. W., Kun L. E. Results of whole-brain irradiation for metastases from small cell carcinoma of the lung. Cancer Treat Rep. 1980 Aug-Sep;64(8-9):957–961. [PubMed] [Google Scholar]
  3. Creaven P. J. The clinical pharmacology of VM26 and VP16-213. A brief overview. Cancer Chemother Pharmacol. 1982;7(2-3):133–140. doi: 10.1007/BF00254535. [DOI] [PubMed] [Google Scholar]
  4. Felletti R., Souhami R. L., Spiro S. G., Geddes D. M., Tobias J. S., Mantell B. S., Harper P. G., Trask C. Social consequences of brain or liver relapse in small cell carcinoma of the bronchus. Radiother Oncol. 1985 Dec;4(4):335–339. doi: 10.1016/s0167-8140(85)80121-3. [DOI] [PubMed] [Google Scholar]
  5. Folkman J. The vascularization of tumors. Sci Am. 1976 May;234(5):58-64, 70-3. doi: 10.1038/scientificamerican0576-58. [DOI] [PubMed] [Google Scholar]
  6. Giannone L., Johnson D. H., Hande K. R., Greco F. A. Favorable prognosis of brain metastases in small cell lung cancer. Ann Intern Med. 1987 Mar;106(3):386–389. doi: 10.7326/0003-4819-106-3-386. [DOI] [PubMed] [Google Scholar]
  7. Greig N. H. Optimizing drug delivery to brain tumors. Cancer Treat Rev. 1987 Mar;14(1):1–28. doi: 10.1016/0305-7372(87)90048-x. [DOI] [PubMed] [Google Scholar]
  8. Hasegawa H., Ushio Y., Hayakawa T., Yamada K., Mogami H. Changes of the blood-brain barrier in experimental metastatic brain tumors. J Neurosurg. 1983 Aug;59(2):304–310. doi: 10.3171/jns.1983.59.2.0304. [DOI] [PubMed] [Google Scholar]
  9. Hirsch F. R., Paulson O. B., Hansen H. H., Larsen S. O. Intracranial metastases in small cell carcinoma of the lung. Prognostic aspects. Cancer. 1983 Feb 1;51(3):529–533. doi: 10.1002/1097-0142(19830201)51:3<529::aid-cncr2820510327>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  10. Kantarjian H., Farha P. A., Spitzer G., Murphy W. K., Valdivieso M. Systemic combination chemotherapy as primary treatment of brain metastasis from lung cancer. South Med J. 1984 Apr;77(4):426–430. doi: 10.1097/00007611-198404000-00005. [DOI] [PubMed] [Google Scholar]
  11. Kristjansen P. E., Hansen H. H. Brain metastases from small cell lung cancer treated with combination chemotherapy. Eur J Cancer Clin Oncol. 1988 Mar;24(3):545–549. doi: 10.1016/s0277-5379(98)90035-9. [DOI] [PubMed] [Google Scholar]
  12. Levin V. A., Crafts D. C., Norman D. M., Hoffer P. B., Spire J. P., Wilson C. B. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg. 1977 Sep;47(3):329–335. doi: 10.3171/jns.1977.47.3.0329. [DOI] [PubMed] [Google Scholar]
  13. Long D. M. Capillary ultrastructure in human metastatic brain tumors. J Neurosurg. 1979 Jul;51(1):53–58. doi: 10.3171/jns.1979.51.1.0053. [DOI] [PubMed] [Google Scholar]
  14. Lucas C. F., Robinson B., Hoskin P. J., Yarnold J. R., Smith I. E., Ford H. T. Morbidity of cranial relapse in small cell lung cancer and the impact of radiation therapy. Cancer Treat Rep. 1986 May;70(5):565–570. [PubMed] [Google Scholar]
  15. Nugent J. L., Bunn P. A., Jr, Matthews M. J., Ihde D. C., Cohen M. H., Gazdar A., Minna J. D. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer. 1979 Nov;44(5):1885–1893. doi: 10.1002/1097-0142(197911)44:5<1885::aid-cncr2820440550>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  16. Spiro S. G., Souhami R. L., Geddes D. M., Ash C. M., Quinn H., Harper P. G., Tobias J. S., Partridge M., Eraut D. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989 Apr;59(4):578–583. doi: 10.1038/bjc.1989.117. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES